Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology, 2006, 24(24):3984-3990. [7] Miller et al. The phase 3...
8.DAVIS I D, MARTIN A J, STOCKLER M R, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer [J]. N Engl J Med, 2019, 381(2): 121-31. 9. FIZAZI K, FOULON S, CARLES J, et ...
Introduction: Prostate cancer is the sixth most common cancer in the world, the second most common cancer among men, and the most common cancer in men in Europe. Metastatic prostate cancer among young patients represents the rarest of the newly diagnosed prostate cancer, with few reports of ...
Deprivation Is a Strong Independent Predictor of Survival in New Metastatic Prostate Cancer: Data From Southwest Oncology Group Trial 9346 (INT-0162). Journal of Clinical Oncology, 2006, 24(24):3984-3990. [7] Miller et al. The phase 3 COU-AA-302 study of Abiraterone acetate plus prednisone ...
For individuals aged 40 years and older, the median age at diagnosis has fallen from 71.8 years to 69.8 years for advanced prostate cancer — a difference of 2 years. But for patients with metastatic breast cancer, the median age at diagnosis, 63.7 years, has not changed. ...
6. Alicia K. Morgans, et al. Progression patterns by types of metastatic spread, prostate-specific antigen (PSA), and clinical symptoms: Post-hoc analyses of ARAMIS. ASCO 2022. Poster 228. 7. Wenzel M, et al. Prostate Cancer Prostatic Dis. 2021 May 30. ...
[1]Chi K M, et al. Final analysis results from TITAN: a phase 3 study of apalutamide vs placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy. J Clin Oncol 39, 2021 (suppl 6; abstr 11). ...
Abiraterone (AA) is indicated in mRCPC (metastatic castration-resistant prostate cancer) before or after chemotherapy, and in mHSPC (metastatic hormone-sensitive prostate cancer) as first line. A decrease in PSA is associated with improved clinical response and increased survival. Recent studies have...
[2]Fizazi K, Tran N, Fein L, Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med.2017 Jul 27;377(4):352-360 *此文仅用于向医学人士提供科学信息,不代表本平台观点
[1] Hu L, et al. Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer. Cancer Manag Res. 2020;12:4369-4377. [2] Guo Z, et al. Eur J Med Res. Docetaxel chemotherapy plus androgen-deprivation th...